Protocol Ledger

NCT06136624 · Phase III · RECRUITING

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Interventional Phase III clinical trial protocol NCT06136624 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-31 Enrollment: 1,310 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06136624
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,310 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06136624
Protocol FieldVerified Registry Value
NCT IdentifierNCT06136624
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,310 participants (ESTIMATED)
Registered Start Date2023-12-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI